If you have read an academic paper, policy brief, or investor report that estimates a drug’s net price in the United States, there is a reasonable chance the underlying data came from SSR Health. The platform occupies a peculiar position in pharmaceutical analytics: it is widely cited, broadly trusted, frequently relied upon for consequential decisions — and almost never subjected to the methodological scrutiny that its influence warrants. SSR has become the field’s default reference for net pricing precisely because no competitor offers anything comparable. Dominance by default is still dominance, and the assumptions embedded in SSR’s methodology propagate through every analysis that uses its data.
The core of SSR’s approach involves estimating net prices by combining publicly reported financial data — revenue, units, gross-to-net adjustments disclosed in SEC filings — with proprietary models of utilization and rebate structures. The result is a set of estimated net prices by product that, over time, has proven broadly consistent with what insiders describe as directionally accurate. For branded drugs with publicly traded manufacturers and transparent financial reporting, SSR’s estimates are considered reliable enough for institutional decision-making. Investors use them to model revenue. Health economists use them for cost-effectiveness analyses. Policy researchers use them to characterize trends in drug spending.
The American Enterprise Institute has published what remains one of the more thorough independent assessments of SSR’s methodology and limitations. The analysis identifies several structural concerns that are worth restating because they are too infrequently discussed relative to how often SSR data is cited.
First, SSR’s volume estimates are weakest for drugs distributed through non-traditional or specialty pharmacy channels. The methodology anchors to prescription volume data that captures retail dispensing more reliably than specialty distribution, where dispensing patterns are fragmented and less uniformly reported. For drugs that are specialty-only — which describes an increasing share of new launches — the volume denominator carries uncertainty that directly affects the estimated net price. An error in volume flows through to the per-unit net price calculation in a way that is difficult to detect from outside the model.
Second, SSR’s course-of-treatment pricing methodology makes assumptions that can diverge significantly from clinical reality. The platform assumes maximum labeled dosing and, where the label does not specify treatment duration, defaults to one year. For drugs used chronically at stable doses — statins, antihypertensives — these assumptions are reasonable. For drugs used episodically, in variable doses, or across multiple indications with different dosing regimens, the assumptions impose a uniformity that the clinical data does not support.
Budesonide illustrates the problem. The drug is used for COPD maintenance, eosinophilic esophagitis induction, Crohn’s disease, and ulcerative colitis, among other conditions. Dosing schedules, treatment durations, and formulations vary across these indications. A course-of-treatment price that assumes maximum labeled dosing and one-year duration describes none of these use cases accurately. It describes a statistical construct — a composite that smooths over the clinical variation that defines how the drug is actually used. The resulting price is defensible as an average. It is unreliable as a description of any specific patient’s cost.
Third, SSR’s assumptions are not publicly documented in sufficient detail for independent replication. Researchers can observe the outputs — estimated net prices, course-of-treatment costs, gross-to-net percentages — but cannot reconstruct the inputs or the intermediate calculations. The methodology is proprietary. This is commercially rational and analytically problematic. When a health economist publishes a cost-effectiveness analysis using SSR data, the analysis inherits whatever assumptions SSR made about volume, channel mix, rebate allocation, and dosing conventions. The economist may disclose that SSR data was used. The economist cannot disclose SSR’s assumptions because SSR does not disclose them.
The practical effect is a dependency chain in which high-stakes decisions rest on estimates produced by a private vendor using undisclosed methods. This is not unique to pharmaceutical pricing — financial markets rely on credit rating agencies, real estate relies on appraisers, and technology relies on benchmark vendors — but the analogy is instructive rather than reassuring. In each of those domains, the consequences of methodological opacity have eventually manifested in ways that surprised the stakeholders who had trusted the ratings without interrogating them.
None of this means SSR’s data is wrong. By most accounts, it is the best available approximation of drug net pricing in the absence of mandatory disclosure. The question is not whether SSR is accurate but whether the confidence placed in its estimates is calibrated appropriately to the uncertainty inherent in its methodology. An estimate that is directionally correct and occasionally precise is useful. An estimate treated as ground truth when it is actually a modeled approximation is dangerous — not because it fails spectacularly, but because it fails subtly, in ways that compound across analyses.
The alternative — mandatory net price disclosure by manufacturers — would render SSR’s estimation methodology unnecessary but faces fierce industry opposition. Manufacturers argue that disclosing net prices would reveal proprietary commercial terms, disrupt competitive dynamics, and potentially reduce the rebates that benefit payers. Whether these concerns outweigh the public interest in transparent drug pricing is a policy question that has been debated for years without resolution.
In the meantime, SSR remains the reference standard. Researchers cite it. Investors subscribe to it. Policy analysts rely on it. And the assumptions it embeds — about volume, dosing, channel mix, and rebate structure — quietly shape the conclusions that all of these stakeholders draw about what drugs cost in America. The gold standard is real. So are its caveats.
